Baker Bros. Advisors LP Cyma Bay Therapeutics, Inc. Transaction History

Baker Bros. Advisors LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$4.23 - $6.55 $3.06 Million - $4.73 Million	-722,812 Reduced 24.98%	2,170,464 $9.85 Million
Q4 2020 Feb 16, 2021	SELL	$5.73 - $9.03 $2.06 Million - $3.24 Million	-359,266 Reduced 11.05%	2,893,276 $16.6 Million
Q3 2020 Nov 16, 2020	BUY	$3.32 - $7.24 $5.74 Million - $12.5 Million	1,729,750 Added 113.59%	3,252,542 $23.5 Million
Q2 2020 Aug 14, 2020	BUY	$1.41 - $4.25 $2.15 Million - $6.47 Million	1,522,792 New	1,522,792 $5.32 Million
Q4 2019 Feb 14, 2020	SELL	$1.33 - $5.93 $7.59 Million - $33.8 Million	-5,707,411 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$8.16 - $13.42 $6.44 Million - $10.6 Million	789,711 Added 16.06%	5,707,411 $75.8 Million
Q2 2018 Aug 14, 2018	BUY	$10.66 - $14.38 $10.7 Million - $14.4 Million	1,000,000 Added 25.53%	4,917,700 $66 Million
Q1 2018 May 15, 2018	BUY	$9.0 - $15.16 $8.33 Million - $14 Million	925,925 Added 30.95%	3,917,700 $50.9 Million
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $17.8 Million - $24.7 Million	2,991,775	2,991,775 $24.1 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.